IgE based therapeutics are an emerging modality in cancer treatment
Open Access
- 25 November 2025
- journal article
- review article
- Published by Springer Nature in Discover Oncology
- Vol. 16 (1) , 2161
Abstract
Targeting human diseases using antibodies is a rapidly evolving area of research that could transform healthcare. Currently, various diseases, including cancer, are treated by immunotherapy using the IgG class of antibodies. Recently, efforts have been made to broaden the range of available treatments by utilizing the distinct features of other antibody classes. Notably, the IgE antibody has shown encouraging results in restricting tumor growth with the first therapeutic antibody MOv18 IgE showing promising results in clinical trials, with good tolerance and safety in patients with ovarian carcinoma. However, several challenges remain. This review discusses recent developments in the engineering of the IgE antibody for cancer therapeutics, focusing on improving manufacturability and reducing immunogenicity by modifying IgE glycosylation complexity. Additionally, bispecific formats of IgE are being established to engage multiple targets simultaneously. Building on the recent studies in these areas, the ongoing research on IgE therapeutics has provided potential opportunities for clinical development and as a therapy in the future. These outcomes and advancements, along with a better clinical safety profile, may increase the treatment options for cancer patients in the future together with existing and approved IgG therapies.Keywords
This publication has 105 references indexed in Scilit:
- Systematic mutational analysis reveals an essential role of N275 in IgE stabilityBiotechnology and Bioengineering, 2024
- Regulation of antibody effector functions through IgG Fc N-glycosylationCellular and Molecular Life Sciences, 2016
- Antibody Glycosylation and Its Impact on the Pharmacokinetics and Pharmacodynamics of Monoclonal Antibodies and Fc-Fusion ProteinsJournal of Pharmaceutical Sciences, 2015
- Using the allergic immune system to target cancer: activity of IgE antibodies specific for human CD20 and MUC1Cancer Immunology, Immunotherapy, 2012
- Recombinant IgE antibody engineering to target EGFRCancer Immunology, Immunotherapy, 2012
- How to connect an IgE-driven response with CTL activity?Cancer Immunology, Immunotherapy, 2011
- Characterisation of an engineered trastuzumab IgE antibody and effector cell mechanisms targeting HER2/neu-positive tumour cellsCancer Immunology, Immunotherapy, 2008
- Activity of human monocytes in IgE antibody‐dependent surveillance and killing of ovarian tumor cellsEuropean Journal of Immunology, 2003
- Comparison of IgE and IgG antibody-dependent cytotoxicityin vitro and in a SCID mouse xenograft model of ovarian carcinomaEuropean Journal of Immunology, 1999
- Growth inhibition of murine mammary carcinoma by monoclonal IgE antibodies specific for the mammary tumor virusCancer Immunology, Immunotherapy, 1991